Latest Insider Transactions at Talis Biomedical Corp (TLIS)
This section provides a real-time view of insider transactions for Talis Biomedical Corp (TLIS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Talis Biomedical Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Talis Biomedical Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 06
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
25,000
+9.13%
|
$25,000
$1.48 P/Share
|
|
Sep 05
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
5,100
+2.23%
|
$5,100
$1.4 P/Share
|
|
Sep 03
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
500
+0.23%
|
$2,000
$4.0 P/Share
|
|
Aug 30
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
151
+0.07%
|
$604
$4.25 P/Share
|
|
Aug 28
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
1,215
+0.55%
|
$3,645
$3.96 P/Share
|
|
Aug 26
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
13,167
+5.73%
|
$39,501
$3.9 P/Share
|
|
Nov 18
2021
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.7%
|
$200,000
$4.37 P/Share
|
|
Aug 13
2021
|
Ramesh Ramakrishnan |
SELL
Open market or private sale
|
Direct |
27,502
-41.59%
|
$192,514
$7.66 P/Share
|
|
Aug 13
2021
|
Ramesh Ramakrishnan |
BUY
Exercise of conversion of derivative security
|
Direct |
52,355
+27.43%
|
$52,355
$1.5 P/Share
|
|
May 17
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Direct |
11,000
+35.48%
|
$110,000
$10.11 P/Share
|
|
May 14
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Direct |
9,000
+50.0%
|
$90,000
$10.16 P/Share
|
|
Feb 17
2021
|
Brian Coe Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
30,931
+29.56%
|
-
|
|
Feb 17
2021
|
Karen E. Flick Chief of Staff, Sr. VP, Legal |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$32,000
$16.0 P/Share
|
|
Feb 17
2021
|
Douglas Liu Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$64,000
$16.0 P/Share
|
|
Feb 17
2021
|
John Roger Moody Jr Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+50.0%
|
$27,200
$16.0 P/Share
|
|
Feb 17
2021
|
Matthew L. Posard Director |
BUY
Open market or private purchase
|
Direct |
62,500
+50.0%
|
$1,000,000
$16.0 P/Share
|
|
Feb 17
2021
|
Ramesh Ramakrishnan |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$16,000
$16.0 P/Share
|
|
Feb 17
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Indirect |
312,500
+50.0%
|
$5,000,000
$16.0 P/Share
|
|
Feb 17
2021
|
Randal W. Scott Director |
BUY
Conversion of derivative security
|
Indirect |
1,390,064
+30.47%
|
-
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Conversion of derivative security
|
Indirect |
391,815
+44.36%
|
-
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Open market or private purchase
|
Indirect |
5,300
+2.4%
|
$84,800
$16.0 P/Share
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Conversion of derivative security
|
Direct |
22,041
+46.09%
|
-
|
|
Feb 17
2021
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
6,250,000
+44.86%
|
$100,000,000
$16.0 P/Share
|